Genprex, Inc. filed a Form 8-K on November 5, 2026, disclosing a press release announcing translational analysis results from patients treated with its lead drug candidate, Reqorsa (quaratusugene ozeplasmid), presented at the Gerontological Society of America 2026 Annual Scientific Meeting.

Key Highlights

  • Conference presentation: A poster titled "TUSC2 Gene Therapy Activates a Transcriptional Program that Enhances Cellular Resilience to Aging-Associated Stress" was presented at the GSA 2026 Annual Scientific Meeting, November 4-7, 2026, in National Harbor, Maryland.
  • Patient sample size: The analysis used whole-blood transcriptomes from 11 lung cancer patients enrolled in two clinical trials evaluating REQORSA.
  • Biphasic response observed: At 5 hours post-administration, innate immune and interferon pathways dominated; by 24 hours, the profile shifted to mitochondrial adaptation, autophagy, lysosomal function, and endoplasmic reticulum quality control.
  • Mitochondrial gene expression: Oxidative phosphorylation genes were transiently suppressed at 5 hours and recovered by 24 hours, according to the filing.
  • Research collaboration: The work was conducted in collaboration with Meharry Medical College in Nashville, Tennessee, pursuant to a sponsored research agreement.
  • TUSC2 biology: The filing states that TUSC2 is a mitochondrial calcium-regulating protein whose expression declines with age, including in the human brain and other metabolically active tissues.

Genprex REQORSA Translational Analysis: Key Findings on TUSC2 and Cellular Aging

According to the filing, Genprex disclosed results from a translational analysis of patients treated with REQORSA, its gene therapy candidate designed to restore tumor-suppressor function through delivery of the TUSC2 gene. The data were presented at the GSA 2026 Annual Scientific Meeting. The filing states that the data "suggest that increased TUSC2 expression, the tumor suppressor gene used in REQORSA, is associated with a systemic transcriptional shift toward cellular maintenance, repair and quality control, a profile consistent with enhanced cellular resilience to aging-associated stress."

The analysis examined samples collected from 11 lung cancer patients before treatment and at 5 and 24 hours after intravenous administration of REQORSA. According to the filing, researchers compared gene expression across the 0-5-hour, 5-24-hour, and 0-24-hour intervals to separate the acute response to delivery from what the filing describes as "the more sustained cellular-remodeling program." The filing noted that at 5 hours the response was "most consistent with a nonspecific host reaction to the lipid nanoparticle delivery system," while by 24 hours, ribosomal, translational, and IGF/mTOR-associated growth pathways were suppressed.

The filing also states that work conducted through the Meharry Medical College collaboration has found that TUSC2 modulates cancer immune responses by boosting Natural Killer cell antitumor activity, and that research collaborators recently published new peer-reviewed preclinical data identifying the role of TUSC2 in maintaining cellular function during brain aging. The company disclosed that the GSA poster has been made available on Genprex's website. The filing notes that NASDAQ:GNPX lists its common stock, par value $0.001 per share, on The Nasdaq Capital Market. The filing contains forward-looking statements that are the company's own and subject to its cautionary language, including risks detailed in Genprex's Annual Report on Form 10-K for the year ended December 31, 2025.

What Was Disclosed

Genprex filed a Form 8-K on November 5, 2026, announcing translational analysis results from 11 lung cancer patients treated with REQORSA, presented at the GSA 2026 Annual Scientific Meeting, showing a biphasic transcriptional response consistent with cellular maintenance pathways at 24 hours post-administration.